Instead, the combined effect of intermittent hypoxia and IL-1β treatment led to the most pronounced expression of IL-19, IL-24 and IL-32 which are known to be dysregulated in inflammatory disorders, such as atherosclerosis (46, 47). The gene discussed is IL1B; the disease is atherosclerosis.